Abstract:Background The long-term safety and efficacy of drug-eluting stents (DES) versus bare metal stents (BMS) are unclear and controversial issues in patients with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PCI). The purpose of this study was to compare the long-term outcome of STEMI patients undergoing primary PCI with DES versus BMS implantation.Methods A total of 191 patients with acute STEMI undergoing PCI from Jan. 2005 to Dec. 2007 were enrolled. Patients received DES (n=83) or BMS (n=108) implantation in the infarction related artery according to physician's discretion. The primary outcome was the occurrence of major adverse cardiac events (MACE), which was defined as a composite of death, myocardial infarction (MI), target vessel revascularization (TVR) and stent thrombosis. The difference of MACE was observed between DES and BMS groups.Results The clinical follow-up duration was 3 years ((41.7 +/- 16.1) months). MACE occurred in 20 patients during three years follow-up. Logistic regression analysis showed that the left ventricular ejection fraction (LVEF) was an independent predictor for MACE in the follow-up period (P=0.0301). There was no significant difference in all-cause mortality (3.61% vs. 7.41%, P=0.2647), the incidence of myocardial infarction (0 vs. 0.93%, P=0.379) and stent thrombosis (1.20% vs. 1.85%, P=0.727) between the DES group and BMS group. The incidence of MACE was significantly lower in the DES group compared to the BMS group (4.82% vs. 14.81%, P=0.0253). The rate of TVR was also lower in the DES group (0 vs. 5.56%, P=0.029). In the DES group, there was no significant difference in the incidence of MACE between sirolimus eluting stents (SES, n=73) and paclitaxel-eluting stents (PES, n=10) subgroups (2.74% vs. 20.00%, P>0.05).Conclusions This finding suggested that drug-eluting stents significantly reduced the need for revascularization in patients with acute STEMI, without increasing the incidence of death or myocardial infarction. Use of DES significantly decreased the incidence of MACE compared with BMS during the 3-year follow-up. Chin Med J 2012;125(16):2803-2806

Enhanced Reendothelialization and Thrombosis Prevention with a New Drug-Eluting Stent

Safety and Efficacy of the Cypher Select Sirolimus-Eluting Stent in the "real World" - Clinical and Angiographic Results from the China Cypher Select Registry

Two-year results and subgroup analyses of the PEPCAD China in-stent restenosis trial: A prospective, multicenter, randomized trial for the treatment of drug-eluting stent in-stent restenosis.

Identification of endothelial protein C receptor as a novel druggable agonistic target for reendothelialization promotion and thrombosis prevention of eluting stent

Design and Rationale of the Targeted Therapy With a Sirolimus-Eluting, Biodegradable Polymer Coronary Stent in Chronic Total Occlusions (TARGET CTO): A Multicenter, Open-Label, Randomized Noninferiority Trial

Design and Rationale of Targeted Therapy With a Sirolimus-Eluting, Biodegradable Polymer Coronary Stent in Chronic Total Occlusions (TARGET CTO): A Multicenter, Open-Label, Randomized Noninferiority Trial.

Accelerated Endothelialization with a Polymer-Free Sirolimus-Eluting Antibody-Coated Stent.

Safety and Efficacy of Cobalt Chromium Alloy Based Sirolimus-Eluting Stent with Bioabsorbable Polymer in Porcine Model.

A TEMPOL and rapamycin loaded nanofiber-covered stent favors endothelialization and mitigates neointimal hyperplasia and local inflammation

Endothelial Progenitor Cells and In-stent Restenosis.

Long-Term Effects of Drug-Eluting Stents Versus Bare Metal Stents on Patients with Acute St-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention: Outcomes of 3-Year Clinical Follow-Up

AS-30: the Preclinical Assessment of a Novel Biodegradable Rapid Prohealing Polymer with Sirolimus -Eluting Coating Stent in Porcine Model

Solely Abluminal Drug Release from Coronary Stents Could Possibly Improve Reendothelialization.

[The Safety and Efficacy of Cypher Drug-Eluting Stent: Results from a Six Months Follow-Up Study in Patients with ST-segment Elevation Myocardial Infarction].

Research Progress of the Drug-Eluting Stents

REDV-Functionalized Recombinant Spider Silk for Next-Generation Coronary Artery Stent Coatings: Hemocompatible, Drug-Eluting, and Endothelial Cell-Specific Materials

Drug Eluting Stents in Treatment of Coronary Artery Disease: Progress in Reserch

A bio-inspired nanoparticle coating for vascular healing and immunomodulatory by cGMP-PKG and NF-kappa B signaling pathways

Coronary Stents Decorated by Heparin/NONOate Nanoparticles for Anticoagulant and Endothelialized Effects.

An organic selenium and VEGF-conjugated bioinspired coating promotes vascular healing

REDV/Rapamycin-loaded Polymer Combinations As a Coordinated Strategy to Enhance Endothelial Cells Selectivity for a Stent System.